{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:08:44Z","timestamp":1788458924396,"version":"build-2803163510"},"reference-count":20,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T00:00:00Z","timestamp":1712275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Cardiol"],"abstract":"<jats:p>Background: Low-dose aspirin lowers cardiovascular event risk; dual-pathway inhibition (DPI) using low-dose aspirin with low-dose rivaroxaban may reduce this risk further. A systematic literature review and meta-analysis compared the efficacy, safety and net clinical benefit (NCB) of DPI with aspirin. Methods: PubMed and Embase were searched for randomised controlled trials reporting clinical efficacy, safety and NCB of DPI compared with aspirin alone in patients with coronary artery disease (CAD) and\/or peripheral artery disease. Six articles representing four trials were included. Results: DPI versus aspirin alone significantly reduced major adverse cardiovascular events (HR 0.77; 95% CI [0.69\u20130.87]; p&lt;0.01), increased International Society on Thrombosis and Haemostasis major bleeding events (HR 1.67; 95% CI [1.37\u20132.02]; p&lt;0.01) and resulted in a significant NCB (HR 0.79; 95% CI [0.70\u20130.90]; p&lt;0.01). Conclusion: These results underscore the potential benefit of DPI in patients with CAD, including those in the immediate post-acute coronary syndrome stage and with established CAD, as well as patients with peripheral artery disease.<\/jats:p>","DOI":"10.15420\/ecr.2023.40","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T11:50:15Z","timestamp":1712317815000},"source":"Crossref","is-referenced-by-count":14,"title":["Dual-pathway Inhibition with Low-dose Aspirin and Rivaroxaban versus Aspirin Monotherapy in Patients with Coronary Artery Disease and Peripheral Artery Disease: Systematic Literature Review and Meta-analysis"],"prefix":"10.15420","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0698-2696","authenticated-orcid":false,"given":"Dirk","family":"Sibbing","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Ludwig-Maximilians-University, Munich, Germany; Privatklinik Lauterbacher M\u00fchle am Ostersee, Seeshaupt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5138-9683","authenticated-orcid":false,"given":"Michael J","family":"Blaha","sequence":"additional","affiliation":[{"name":"Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins Medicine, Baltimore, MD, US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0263-9971","authenticated-orcid":false,"given":"Rajinder","family":"Chawla","sequence":"additional","affiliation":[{"name":"AccuScript Consultancy, Ludhiana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1257-9211","authenticated-orcid":false,"given":"Augusto","family":"Lavalle-Cobo","sequence":"additional","affiliation":[{"name":"Cardiology Centre, Sanatorio Otamendi, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Kishore","sequence":"additional","affiliation":[{"name":"AccuScript Consultancy, Ludhiana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5932-2889","authenticated-orcid":false,"given":"Angel","family":"Lanas","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Zaragoza, Zaragoza, Spain; IIS Arag\u00f3n, Zaragoza, Spain; CIBEREHD, CIBER, Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[{"name":"Medical Affairs and Pharmacovigilance, Pharmaceuticals, Bayer AG, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4593-905X","authenticated-orcid":false,"given":"Francesca","family":"Santilli","sequence":"additional","affiliation":[{"name":"Department of Medicine and Aging, D\u2019Annunzio University of Chieti-Pescara, Chieti, Italy; Center for Advanced Studies and Technology, D\u2019Annunzio University of Chieti-Pescara, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Schnell","sequence":"additional","affiliation":[{"name":"Forschergruppe Diabetes e.V., Munich Helmholtz Center, Munich-Neuherberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9919-0830","authenticated-orcid":false,"given":"Zhongwei","family":"Shi","sequence":"additional","affiliation":[{"name":"Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2024,4,5]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Kapoor JR. Platelet activation and atherothrombosis. N Engl J Med 2008;358:1638; author reply 1638\u20139. https:\/\/doi.org\/10.1056\/NEJMc080056; PMID: 18403776.","DOI":"10.1056\/nejmc080056"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Capodanno D, Bhatt DL, Eikelboom JW, et al. Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. Nat Rev Cardiol 2020;17:242\u201357. https:\/\/doi.org\/10.1038\/s41569-019-0314-y; PMID: 31953535.","DOI":"10.1038\/s41569-019-0314-y"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Antithrombotic Trialists\u2019 (ATT) Collaboration, Baigent C, Blackwell L, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(09)60503-1; PMID: 19482214.","DOI":"10.1016\/s0140-6736(09)60503-1"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Mega JL, Braunwald E, Mohanavelu S, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009;374:29\u201338. https:\/\/doi.org\/10.1016\/S0140-6736(09)60738-8; PMID: 19539361.","DOI":"10.1016\/s0140-6736(09)60738-8"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366:9\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1112277; PMID: 22077192.","DOI":"10.1056\/NEJMoa1112277"},{"key":"ref5","unstructured":"Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017;377:1319\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1709118; PMID: 28844192."},{"key":"ref6","unstructured":"Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med 2020;382:1994\u20132004. https:\/\/doi.org\/10.1056\/NEJMoa2000052; PMID: 32222135."},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Obonska K, Navarese EP, Lansky A, et al. Low-dose of oral factor Xa inhibitors in patients with a recent acute coronary syndrome: a systematic review and meta-analysis of randomized trials. Atherosclerosis 2013;229:482\u20138. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2013.04.022; PMID: 23672879.","DOI":"10.1016\/j.atherosclerosis.2013.04.022"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Oldgren J, Wallentin L, Alexander JH, et al. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. Eur Heart J 2013;34:1670\u201380. https:\/\/doi.org\/10.1093\/eurheartj\/eht049; PMID: 23470494.","DOI":"10.1093\/eurheartj\/eht049"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Villablanca PA, Holmes D Jr, Mohananey D, et al. Direct Xa inhibitors in addition to antiplatelet therapy in acute coronary syndrome: meta-analysis of randomized trials. Coron Artery Dis 2017;28:395\u2013405. https:\/\/doi.org\/10.1097\/MCA.0000000000000485; PMID: 28328784.","DOI":"10.1097\/mca.0000000000000485"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Chen C, Kan Y, Shi Z, et al. Low dose rivaroxaban for atherosclerotic cardiovascular diseases: a systematic review and meta-analysis. Front Pharmacol 2020;11:608247. https:\/\/doi.org\/10.3389\/fphar.2020.608247; PMID: 33732144.","DOI":"10.3389\/fphar.2020.608247"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Khan SU, Khan MZ, Asad ZUA, et al. Efficacy and safety of low dose rivaroxaban in patients with coronary heart disease: a systematic review and meta-analysis. J Thromb Thrombolysis 2020;50:913\u201320. https:\/\/doi.org\/10.1007\/s11239-020-02114-7; PMID: 32281069.","DOI":"10.1007\/s11239-020-02114-7"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71; PMID: 33782057.","DOI":"10.1136\/bmj.n71"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Higgins JPT, Savovi\u0107 J, Page MJ, et al. Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, et al., eds. Cochrane Handbook for Systematic Reviews of Interventions. version 63. Cochrane, 2022.","DOI":"10.1002\/9781119536604.ch8"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ 2017;358:j4008. https:\/\/doi.org\/10.1136\/bmj.j4008; PMID: 28935701.","DOI":"10.1136\/bmj.j4008"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Hiatt WR, Bonaca MP, Patel MR, et al. Rivaroxaban and aspirin in peripheral artery disease lower extremity revascularization: impact of concomitant clopidogrel on efficacy and safety. Circulation 2020;142:2219\u201330. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.050465; PMID: 33138628.","DOI":"10.1161\/circulationaha.120.050465"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Gibson WJ, Gibson CM, Yee MK, et al. Safety and efficacy of rivaroxaban when added to aspirin monotherapy among stabilized post acute coronary syndrome patients: a pooled analysis study of ATLAS ACS-TIMI 46 and ATLAS ACS-TIMI 51. J Am Heart Assoc 2019;8:e009451. https:\/\/doi.org\/10.1161\/JAHA.118.009451; PMCID: PMC6474929.","DOI":"10.1161\/jaha.118.009451"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Steffel J, Eikelboom JW, Anand SS, et al. The COMPASS trial: net clinical benefit of low-dose rivaroxaban plus aspirin as compared with aspirin in patients with chronic vascular disease. Circulation 2020;142:40\u20138. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.046048; PMID: 32436455.","DOI":"10.1161\/circulationaha.120.046048"},{"key":"ref18","unstructured":"Collet JP, Thiele H, Barbato E, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021;42:1289\u2013367. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa575; PMID: 32860058."},{"key":"ref19","unstructured":"Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020;41:407\u201377. https:\/\/doi.org\/10.1093\/eurheartj\/ehz425; PMID: 31504439."}],"container-title":["European Cardiology Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ecrjournal.com\/articleindex\/ecr.2023.40","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T06:13:55Z","timestamp":1712384035000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ecrjournal.com\/articleindex\/ecr.2023.40"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,5]]},"references-count":20,"URL":"https:\/\/doi.org\/10.15420\/ecr.2023.40","relation":{},"ISSN":["1758-3764","1758-3756"],"issn-type":[{"value":"1758-3764","type":"electronic"},{"value":"1758-3756","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,5]]},"article-number":"e01"}}